Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

3.6K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

2.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

2.2K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exploratory Analysis of the Neutrophil-to-Lymphocyte Ratio (NLR) and Mucositis Severity in Head and Neck Cancer Patients Undergoing Radiotherapy-Based Treatment: A Retrospective Study.

Journal of clinical medicine·2026
Same author

Late peritoneal carcinomatosis from cutaneous melanoma mimicking ovarian cancer.

Melanoma research·2025
Same author

Longitudinal prediction of drug response in high-grade serous ovarian cancer organoid cultures aligning with clinical responses.

Journal of advanced research·2025
Same author

Novel De Novo <i>BRCA2</i> Variant in an Early-Onset Ovarian Cancer Reveals a Unique Tumor Evolution Pathway.

International journal of molecular sciences·2025
Same author

Multiple myeloma refractory to lenalidomide: A systematic literature review of trials and real-world evidence.

British journal of haematology·2024
Same author

The extracellular matrix protein EMILIN-1 impacts on the microenvironment by hampering gastric cancer development and progression.

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association·2024

Related Experiment Video

Updated: Apr 24, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

6.1K

Maintenance therapy for multiple myeloma.

Philip L McCarthy1, Antonio Palumbo2

  • 1Department of Medicine, Blood and Marrow Transplant Program, Roswell Park Cancer Institute, State University of New York at Buffalo, Elm and Carlton Streets, Buffalo, NY 14263, USA.

Hematology/Oncology Clinics of North America
|September 13, 2014
PubMed
Summary
This summary is machine-generated.

Multiple myeloma (MM) treatment has advanced with new drugs and stem cell transplants, improving survival for elderly patients. Optimal maintenance therapy aims for sustained response with minimal side effects.

Keywords:
BortezomibLenalidomideMaintenanceMultiple myelomaThalidomideTransplant-eligibleTransplant-ineligible

More Related Videos

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

5.7K
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

12.5K

Related Experiment Videos

Last Updated: Apr 24, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

6.1K
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

5.7K
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

12.5K

Area of Science:

  • Hematology
  • Oncology
  • Geriatric Medicine

Background:

  • Multiple myeloma (MM) is a common cancer in older adults, typically diagnosed around age 70.
  • Recent therapeutic advances include autologous hematopoietic stem cell transplantation (AHSCT), immunomodulatory drugs, and proteasome inhibitors.
  • Novel agents incorporated into induction therapy have significantly improved overall survival rates.

Purpose of the Study:

  • To define the characteristics of optimal maintenance therapy for multiple myeloma.
  • To ensure sustained patient response post-induction and autologous hematopoietic stem cell transplantation (AHSCT).
  • To identify therapies balancing efficacy with minimal toxicity and ease of administration.

Main Methods:

  • Review of current multiple myeloma treatment paradigms.
  • Analysis of data regarding novel agents in induction and maintenance therapy.
  • Evaluation of treatment outcomes, including response rates and survival.

Main Results:

  • Incorporation of novel agents into induction therapy has led to improved overall survival.
  • Maintenance therapy is crucial for sustaining response after initial treatment and AHSCT.
  • The ideal maintenance regimen should be effective, well-tolerated, and convenient for elderly patients.

Conclusions:

  • Optimal maintenance therapy is essential for long-term management of multiple myeloma.
  • Balancing efficacy, safety, and patient convenience is key in selecting maintenance strategies.
  • Continued research is needed to refine maintenance protocols for improved patient outcomes.